Immunologic and Virologic Parameters of the Study Group
| . | Controls . | CDC . | CDC . | CDC . |
|---|---|---|---|---|
| . | (n = 12) . | Group A . | Group B . | Group C . |
| . | . | (n = 12) . | (n = 11) . | (n = 10) . |
| TNF-α (pg/mL) | 0 | 26* | 28* | 40* |
| (0-8) | (20-36) | (22-44) | (29-70) | |
| Soluble p55-TNFR (ng/mL) | 1.25 | 1.95† | 2.18‡ | 3.19* |
| (1.14-1.75) | (1.51-2.21) | (1.88-4.70) | (2.30-3.94) | |
| Soluble p75-TNFR (ng/mL) | 1.43 | 4.15‡ | 5.38* | 13.10* |
| (1.32-1.82) | (3.70-6.38) | (3.71-8.87) | (8.00-16.90) | |
| CD4+ lymphocytes (106/L) | 690 | 310* | 110* | 20* |
| (550-810) | (200-400) | (70-190) | (10-35) | |
| HIV RNA copies (×103) per mL plasmaρ | — | 18.1 | 71.2 | 405.7 |
| (8.6-22.6) | (16.1-290.1) | (161.3-627.7) |
| . | Controls . | CDC . | CDC . | CDC . |
|---|---|---|---|---|
| . | (n = 12) . | Group A . | Group B . | Group C . |
| . | . | (n = 12) . | (n = 11) . | (n = 10) . |
| TNF-α (pg/mL) | 0 | 26* | 28* | 40* |
| (0-8) | (20-36) | (22-44) | (29-70) | |
| Soluble p55-TNFR (ng/mL) | 1.25 | 1.95† | 2.18‡ | 3.19* |
| (1.14-1.75) | (1.51-2.21) | (1.88-4.70) | (2.30-3.94) | |
| Soluble p75-TNFR (ng/mL) | 1.43 | 4.15‡ | 5.38* | 13.10* |
| (1.32-1.82) | (3.70-6.38) | (3.71-8.87) | (8.00-16.90) | |
| CD4+ lymphocytes (106/L) | 690 | 310* | 110* | 20* |
| (550-810) | (200-400) | (70-190) | (10-35) | |
| HIV RNA copies (×103) per mL plasmaρ | — | 18.1 | 71.2 | 405.7 |
| (8.6-22.6) | (16.1-290.1) | (161.3-627.7) |
Serum levels of TNF-α and sTNFRs (p55 and p75), plasma levels of HIV RNA copies and CD4+ lymphocyte counts in PB in three clinical groups of HIV-1–infected patients and in healthy controls; asymptomatic HIV-1–infected patients (CDC group A), symptomatic non-AIDS HIV-1–infected patients (CDC group B), and AIDS patients (CDC group C). Data are given as medians and 25th to 75th percentiles.
P < .001 versus controls.
P < .05 versus controls.
P < .01 versus controls.
ρ HIV RNA copies in plasma were analyzed in 24 patients only.